Enfermedades Neurodegenerativas: desarrollo de terapias
Buscador de publicaciones
Sólo se han incluido artículos originales, editoriales y revisiones.
-
Palomares, Belen, Garrido-Rodriguez, Martin, Gonzalo-Consuegra, Claudia, Gomez-Canas, Maria, Saen-oon, Suwipa, Soliva, Robert, Collado, Juan A., Fernandez-Ruiz, Javier, Morello, Gaetano, Calzado, Marco A., Appendino, Giovanni, Muñoz E.
Delta(9)-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPAR gamma and CB(1)receptors
BRITISH JOURNAL OF PHARMACOLOGY . 177(17): 4034-4054. Nº de citas: 9
-
Espadas, Isabel, Keifman, Ettel, Palomo-Garo, Cristina, Burgaz, Sonia, Garcia, Concepcion, Fernandez-Ruiz, Javier, Moratalla, Rosario.
Beneficial effects of the phytocannabinoid Delta(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
NEUROBIOLOGY OF DISEASE . 141: 104892-104892. Nº de citas: 15
-
Fernandez-Ruiz, Javier, Galve-Roperh, Ismael, Sagredo, Onintza, Guzman, Manuel.
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
EUROPEAN NEUROPSYCHOPHARMACOLOGY . 36: 217-234. Nº de citas: 19
-
Martinez-Gonzalez, Loreto, Rodriguez-Cueto, Carmen, Cabezudo, Diego, Bartolome, Fernando, Andres-Benito, Pol, Ferrer, Isidro, Gil, Carmen, Martin-Requero, Angeles, Fernandez-Ruiz, Javier, Martinez, Ana, de Lago, Eva.
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1 delta kinase inhibitor treatment
SCIENTIFIC REPORTS . 10(1): 4449-4449. Nº de citas: 35
-
Fernandez-Trapero, Maria, Perez-Diaz, Carmen, Espejo-Porras, Francisco, de Lago, Eva, Fernandez-Ruiz, Javier.
Pharmacokinetics of Sativex (R) in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
Biomolecules . 10(2): . Nº de citas: 17
-
Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holzgrabe U.
Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
FRONTIERS IN PHARMACOLOGY . 10: 1284-1284. Nº de citas: 5
-
Ceprián M, Vargas C, García-Toscano L, Penna F, Jiménez-Sánchez L, Achicallende S, Elezgarai I, Grandes P, Hind W, Pazos MR, Martínez-Orgado J.
Cannabidiol Administration Prevents Hypoxia-Ischemia-Induced Hypomyelination in Newborn Rats.
FRONTIERS IN PHARMACOLOGY . 10: 1131-1131. Nº de citas: 16
-
Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J.
Development of An Oral Treatment with the PPAR-?-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.
Molecules . 24(15): . Nº de citas: 17
-
Ucha M, Coria SM, Núñez AE, Santos-Toscano R, Roura-Martínez D, Fernández-Ruiz J, Higuera-Matas A, Ambrosio E.
Morphine self-administration alters the expression of translational machinery genes in the amygdala of male Lewis rats.
JOURNAL OF PSYCHOPHARMACOLOGY . 33(7): 882-893. Nº de citas: 6
-
Fernández-Ruiz J.
The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.
BRITISH JOURNAL OF PHARMACOLOGY . 176(10): 1370-1383. Nº de citas: 31
-
Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernández-Ruiz J.
Targeting glial cannabinoid CB 2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.
BRITISH JOURNAL OF PHARMACOLOGY . 176(10): 1585-1600. Nº de citas: 30
-
Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández-Gálvez M, Fernández-Ruiz J.
Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets.
FRONTIERS IN MOLECULAR NEUROSCIENCE . 12: 94-94. Nº de citas: 8
-
Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J.
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders.
BIOCHEMICAL PHARMACOLOGY . 157: 85-96. Nº de citas: 9
-
Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J.
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
BIOCHEMICAL PHARMACOLOGY . 157: 67-84. Nº de citas: 51
-
Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido M, Fernández-Ruiz J, Muñoz E, de Lago E.
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1 G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis.
BIOCHEMICAL PHARMACOLOGY . 157: 217-226. Nº de citas: 33
-
Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C, López-Pedrera C, Appendino G, Calzado MA, Muñoz E.
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR?- and CB 2 receptor-dependent pathways.
BRITISH JOURNAL OF PHARMACOLOGY . 175(19): 3813-3831. Nº de citas: 21
-
Espejo-Porras F, Fernández-Ruiz J, de Lago E.
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION . 19(5-6): 377-386. Nº de citas: 14
-
García C, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo-Garo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Luz Bellido M, García-Arencibia M, Ruth Pazos M, Muñoz E, Fernández-Ruiz J.
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR? receptor.
JOURNAL OF NEUROINFLAMMATION . 15(1): 19-19. Nº de citas: 32